|
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
|
Pre-commencement communication pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
|
Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Emerging growth company
|
Item 8.01
|
Other Events.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
99.1 |
Press Release dated April 28, 2021, providing an update on Adverum Biotechnologies, Inc.’s INFINITY trial evaluating ADVM-022 in patients with diabetic macular edema.
|
104 |
Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101)
|
Adverum Biotechnologies, Inc.
|
||
Date: April 28, 2021
|
By:
|
/s/ Laurent Fischer, M.D.
|
Laurent Fischer, M.D.
|
||
Chief Executive Officer
|